PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 8, 2026ESMO Open5 citationsOpen Access

Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC

NGN. GirardJBJ. BarPBP. Baas

Key Points

  • To evaluate the long-term outcomes of durvalumab following chemoradiotherapy in patients with unresectable stage III non-small cell lung cancer.
  • Analysis of mature data from the PACIFIC-R cohort
  • Focus on overall survival (OS) and real-world progression-free survival (rwPFS)
  • Assessment of durvalumab as a consolidation therapy
  • Durvalumab shows improved overall survival in the cohort
  • Real-world progression-free survival supports effective treatment outcomes
  • Findings advocate for durvalumab as standard of care in this patient population

Abstract

PACIFIC-R provides mature data on OS and rwPFS from a large, real-world cohort, supporting consolidation durvalumab as a standard of care in this setting.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Girard et al. (2026) studied this question.

synapsesocial.com/papers/6988270a0fc35cd7a8845eb6https://doi.org/10.1016/j.esmoop.2026.106070
Ask AI
Helpful
Bookmark
Share
View Full Paper